Comparison between Innovatiview IPO and Veeda Clinical Research IPO.
Innovatiview IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Veeda Clinical Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Innovatiview IPO is up to ₹2,000.00 Cr whereas the issue size of the Veeda Clinical Research IPO is up to ₹0.00 Cr. The final issue price of Innovatiview IPO is and of Veeda Clinical Research IPO is .
| Innovatiview IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Face Value | ₹5 per share | ₹2 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹185.00 Cr |
| OFS Issue Size | 0 shares | 1,30,08,128 shares |
| OFS Issue Size (Amount) | up to ₹2,000.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹2,000.00 Cr | up to ₹0.00 Cr |
Innovatiview IPO opens on , while Veeda Clinical Research IPO opens on . The closing date of Innovatiview IPO and Veeda Clinical Research IPO is , and , respectively.
Innovatiview IPO P/E ratio is , as compared to Veeda Clinical Research IPO P/E ratio of .
| Innovatiview IPO | Veeda Clinical Research IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 33.83 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 52.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 58.94% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.24 | 0.32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 53.20% | -0.02% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Innovatiview IPO Retail Individual Investors (RII) are offered 0 shares while in Veeda Clinical Research IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Innovatiview IPO and in Veeda Clinical Research IPO.
| Innovatiview IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 0 shares | |
| QIB | 0 shares | |
| NII | 0 shares | |
| RII | 0 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 0 shares |
Innovatiview IPO subscribed in total, whereas Veeda Clinical Research IPO subscribed .
| Innovatiview IPO | Veeda Clinical Research IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
